secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001437749-24-031806
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

European Patent Office intends to grant patent for Allarity's DRP companion diagnostic for stenoparib
--------------------------------------------------------------------------------

- EPO issued formal notice of intention to grant patent for DRP companion diagnostic for stenoparib, a PARP/Tankyrase inhibitor.
- Patent covers use of DRP to identify cancer patients most likely to benefit from stenoparib treatment.
- Patent applications for Stenoparib DRP also pending in US, Japan, China, Australia, and India.
- Allarity now has 17 granted DRP patents, including 8 in the US, strengthening its intellectual property portfolio.
- CEO Thomas Jensen stated the patent is key for securing international market position ahead of potential commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924031806/0001437749-24-031806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924031806/allr20241022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-031806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer